Toll free

18002022232

Toll free

18002022232

Therapies

What is CAR T - cell Therapy?

CAR T (Chimeric Antigen Receptor T ‐ cell) therapy is a revolutionary cancer treatment that uses a patient’s own immune cells or donor cells, to fight cancer.

How does Autologous CAR T - cell Therapy work?

  1. Collection: T ‐ cells are collected from the patient’s blood through leukapheresis.
  2. Modification: The collected T ‐ cells are genetically engineered in a laboratory to express Chimeric Antigen Receptors (CARs) on their surface, enhancing their ability to target cancer cells.
  3. Expansion: The modified T ‐ cells are multiplied in number to increase their effectiveness.
  4. Infusion: The CAR T ‐ cells are infused back into the patient’s bloodstream after the patient undergoes conditioning therapy.
  5. Targeting Cancer: These engineered CAR T ‐ cells recognize and attack cancer cells throughout the body, helping eliminate tumors and improve patient outcomes.

Autologous CAR T - cell Therapy

  1. Source: Uses the patient’s own T ‐ cells
  2. Availability; Requires weeks to modify and expand cells
  3. Risk of Rejection: Lower risk (cells from self)
  4. Cost: Higher due to personalization
  5. Suitability: Best for patients who can wait
  6. Procedure: Cells collected from the patient, modified, expanded, and reinfused
  7. Process: Requires patient-specific T ‐ cell collection, genetic modification, and expansion before infusion

Benefits

Personalized Treatment : Uses the patient’s own cells, reducing the risk of rejection.

Targeted Action : Specifically designed to attack cancer cells.

Potential for Long-Term Remission : Some patients experience prolonged remission after treatment.

SunAct genitourinary cancer case study on GPC3-targeted CAR T therapy for refractory non-seminomatous germ cell tumor
SunAct genitourinary cancer case study on GPC3-targeted CAR T therapy for refractory non-seminomatous germ cell tumor
SunAct colon cancer case study highlighting TCR-based approach in metastatic colon cancer with lung lesions
SunAct colon cancer case study highlighting TCR-based approach in metastatic colon cancer with lung lesions
SunAct breast cancer case study showcasing HER2-positive treatment with CAR T-cell therapy
SunAct breast cancer case study showcasing HER2-positive treatment with CAR T-cell therapy
SunAct head and neck cancer case study using TCR-p53 therapy in inoperable squamous cell carcinoma
SunAct case study featuring gamma delta T-cell therapy for recurrent tongue carcinoma with extensive metastasis
SunAct case study featuring gamma delta T-cell therapy for recurrent tongue carcinoma with extensive metastasis
SunAct head and neck cancer case study on salivary ductal carcinoma managed with advanced therapies
SunAct head and neck cancer case study on salivary ductal carcinoma managed with advanced therapies
SunAct case study on GD2-targeted CAR T therapy for diffuse midline glioma in a 22-year-old male
SunAct case study on GD2-targeted CAR T therapy for diffuse midline glioma in a 22-year-old male
SunAct CNS case study on GBM treatment using multiple gene mutation targeting in a 36-year-old male
SunAct CNS case study on GBM treatment using multiple gene mutation targeting in a 36-year-old male